Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human TRAF3IP2 Antibodies:
anti-Mouse (Murine) TRAF3IP2 Antibodies:
anti-Rat (Rattus) TRAF3IP2 Antibodies:
Go to our pre-filtered search.
Human Polyclonal TRAF3IP2 Primary Antibody for IHC (p), SimWes - ABIN4361705
Valente, Yoshida, Clark, Delafontaine, Siebenlist, Chandrasekar: Advanced oxidation protein products induce cardiomyocyte death via Nox2/Rac1/superoxide-dependent TRAF3IP2/JNK signaling. in Free radical biology & medicine 2013
Show all 6 Pubmed References
Human Polyclonal TRAF3IP2 Primary Antibody for ELISA, WB - ABIN4361709
Qian, Liu, Hartupee, Altuntas, Gulen, Jane-Wit, Xiao, Lu, Giltiay, Liu, Kordula, Zhang, Vallance, Swaidani, Aronica, Tuohy, Hamilton, Li: The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. in Nature immunology 2007
Human Polyclonal TRAF3IP2 Primary Antibody for WB - ABIN2472995
Leonardi, Chariot, Claudio, Cunningham, Siebenlist: CIKS, a connection to Ikappa B kinase and stress-activated protein kinase. in Proceedings of the National Academy of Sciences of the United States of America 2000
AP1 (show FOSB Antibodies) binding sites were enriched upstream of genes up-regulated by TRAF3IP2 silencing. Correspondingly, nuclear expression of FosB (show FOSB Antibodies) and Fra1 (show FOSL1 Antibodies) was increased in TRAF3IP2-silenced cells. Many genes involved in host defense were induced by IL-17 (show IL17A Antibodies) in a TRAF3IP2-dependent fashion.
TRAF3IP2 SNP rs33980500 associated with no achievement of low disease activity nor remission at 6 months
the first report to describe a non-adaptor function of Act1 by directly binding to the promoter region of IL-17A (show IL17A Antibodies) responsive genes and directly regulate their transcription.
ACT1 is an essential adaptor molecule of Il-17 (show IL17A Antibodies)-induced expression of inflammation-related gene targets.
Both the ACT-1 assay and the MAdCAM-1 (show MADCAM1 Antibodies) assay demonstrated acceptable reproducibility and repeatability. The assays were sufficiently stable to allow for clinical use. During clinical testing the assays demonstrated that vedolizumab was able to saturate peripheral cells at all doses tested.
A G/G genotype of rs766748 in IL-17F (show IL17F Antibodies), and a C/C or C/A genotype of rs1883136 in TRAF3IP2.
The suppressive effects of miR (show MLXIP Antibodies)-30a were mediated by directly targeting Traf3ip2 mRNA
TRAF3IP2 may play a causal role in aldosterone-induced adverse cardiac remodeling in vivo.
Single nucleotide polymorphisms in RBPJ (show RBPJ Antibodies), IL1R1 (show IL1RN Antibodies), REV3L (show REV3L Antibodies), TRAF3IP2, IRF1 (show IRF1 Antibodies) and ICOS (show CTLA4 Antibodies) showed association with rheumatoid arthritis in black South Africans.
A variant (rs76228616 SNP) in TRAF3IP2 gene could be involved in susceptibility to Steven-Johnson Syndrome.
TRAF3IP2 plays a causal role in atherosclerotic plaque development and vulnerability, possibly by inducing the expression of multiple proinflammatory mediators
TRAF3IP2 is a critical signaling intermediate in aldosterone/salt-induced myocardial hypertrophy and fibrosis, and thus a potential therapeutic target in hypertensive heart disease.
ameliorating myocardial damage by targeting TRAF3IP2 appears to be more effective to inhibiting its downstream signaling intermediates NF-kappaB (show NFKB1 Antibodies) and JNK (show MAPK8 Antibodies). Therefore, TRAF3IP2 could be a potential therapeutic target in ischemic heart disease
these results demonstrate that overexpression of TRAF3IP2 in male mice is sufficient to induce myocardial hypertrophy, cardiac fibrosis, and contractile dysfunction.
using massively parallel reporter assays, we dissect the enhancer activity of three liver eExons (SORL1 (show SORL1 Antibodies) exon 17, TRAF3IP2 exon 2, PPARG (show PPARG Antibodies) exon 6) at single nucleotide resolution in the mouse liver
TRAF3IP2 is a critical intermediate in IL-18 (show IL18 Antibodies)-induced cardiac fibroblast migration and differentiation in vitro.
Our results support the important role of Act1 in the regulation of self-reactive B cells and reveal how Act1 functions to prevent the production of autoantibodies.
These results demonstrate for the first time that AOPPs induce cardiomyocyte death via Nox2/Rac1/superoxide-dependent
CIKS knockdown inhibited high glucose-induced IKKbeta (show IKBKB Antibodies) and JNK (show MAPK8 Antibodies) phosphorylation, p65 (show NFkBP65 Antibodies) and c-Jun (show JUN Antibodies) nuclear translocation, and NF-kappaB (show NFKB1 Antibodies)- and AP-1 (show JUN Antibodies)-dependent proinflammatory cytokine, chemokine (show CCL1 Antibodies), and adhesion molecule (show NCAM1 Antibodies) expression.
The findings define a new role for the IKK-related kinases in suppressing IL-17-mediated NF-kappaB activation through TRAF6-dependent Act1 phosphorylation.
This gene encodes a protein involved in regulating responses to cytokines by members of the Rel/NF-kappaB transcription factor family. These factors play a central role in innate immunity in response to pathogens, inflammatory signals and stress. This gene product interacts with TRAF proteins (tumor necrosis factor receptor-associated factors) and either I-kappaB kinase or MAP kinase to activate either NF-kappaB or Jun kinase. Several alternative transcripts encoding different isoforms have been identified. Another transcript, which does not encode a protein and is transcribed in the opposite orientation, has been identified. Overexpression of this transcript has been shown to reduce expression of at least one of the protein encoding transcripts, suggesting it has a regulatory role in the expression of this gene.
NFkB-activating protein ACT1
, adapter protein CIKS
, connection to IKK and SAPK/JNK
, nuclear factor NF-kappa-B activator 1
, TRAF3 interacting protein 2
, adapter protein CIKS-like